Jakarta, October 30, 2024. Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the Company) as of September 30, 2024, and for the period ending on that date (Unaudited), the Company hereby announces that in the third quarter of 2024, its Net Sales reached IDR 23,190.15 billion, reflecting an increase of 9.74% compared to the Net Sales of IDR 21,132.83 billion in the third quarter of 2023.

The Company's Cost of Goods Sold in the third quarter of 2024 was IDR 20,920.02 billion, a 10.34% increase compared to IDR 18,959.33 billion in the third quarter of 2023.

As a result, the Company recorded a Gross Profit of IDR 2,270.13 billion in the third quarter of 2024, growing 4.45% compared to the Gross Profit of IDR 2,173.50 billion in the third quarter of 2023.

In the third quarter of 2024, the Company's Operating Expenses totaled IDR 1,536.79 billion, comprising Selling Expenses of IDR 1,349.33 billion and General and Administrative Expenses of IDR 187.47 billion, representing an increase of 3.66% compared to the third quarter of 2023. This resulted in the Company recording an Operating Profit of IDR 733.34 billion, up 6.12% compared to the Operating Profit of IDR 691.04 billion in the third quarter of 2023.

The Company Income Before Income Tax Expenses for the third quarter of 2024 amounted to IDR 755.39 billion, marking an increase of 8.41% compared to the same period in 2023. The composition of Other Income (Expenses) includes Financial Income of IDR 10.94 billion, Financial Expenses of IDR 17.40 billion, Final Tax Expenses of IDR 3.26 billion, Share of Net Income of Associates of IDR 6.07 billion, Other Operating Income of IDR 29.51 billion, and Other Operating Expenses of IDR 3.82 billion.

The Company's Income Tax Expenses in the third quarter of 2024 were IDR 169.97 billion, a 9.01% increase compared to IDR 155.93 billion in the same period of 2023.

Thus, the Company reported a Net Profit for the Period of IDR 585.41 billion in the third quarter of 2024, an increase of 8.24% compared to IDR 540.86 billion in the same period of 2023.

Comparing the Company Consolidated Statement of Financial Position as of September 30, 2024 (Unaudited), with the Audited Statement as of December 31, 2023, the Company Total Assets increased by 2.79%, from IDR 10.96 trillion to IDR 11.26 trillion. The Company Total Liabilities rose by 4.66%, from IDR 3.66 trillion as of December 31, 2023, to IDR 3.83 trillion in the third quarter of 2024. Consequently, the Company Total Equity increased by 1.86%, from IDR 7.30 trillion to IDR 7.43 trillion in the third quarter of 2024.

Performance of Each Division

The Company currently has seven divisions, consisting of Consumer Goods, Prescription Drugs, Over-the-Counter Drugs, Raw Materials for Sale, Medical Equipment, Animal and Livestock Medicine, and Health and Transportation Services.

Details of each division's performance are as follows:

• Consumer Goods Division, contributing the largest share to total Net Sales at 39.37%. In the third quarter of 2024, this division achieved Net Sales of IDR 9,128.88 billion, an increase of 4.32% compared to the same period in 2023.
• Prescription Drugs Division, with the second-largest contribution at 33.67%. By the third quarter of 2024, this division achieved Net Sales of IDR 7,809.05 billion, growing by 16.93% compared to the same period in 2023.
• Over-the-Counter Drugs Division recorded Net Sales of IDR 3,139.47 billion in the third quarter of 2024, with a contribution of 13.54%, an increase of 11.70% compared to the same period in 2023.
• Raw Materials for Sale Division recorded Net Sales of IDR 1,830.70 billion in the third quarter of 2024, an increase of 5.47% compared to the same period in 2023, contributing 7.89%.
• Medical Equipment Division contributed 5.12% in the third quarter of 2024, with recorded Net Sales of IDR 1,187.27 billion, growing 13.14% compared to the same period in 2023.
• Animal and Livestock Medicine Division recorded Net Sales of IDR 39.88 billion, an increase of 6.23% compared to the same period in 2023, contributing 0.17% to the Company total Net Sales.
• Health and Transportation Services Division recorded Net Sales of IDR 54.90 billion, down 21.86% compared to the same period in 2023, contributing 0.24%.

About Enseval

Enseval is Indonesia largest distribution company, having commenced distribution activities in 1973 and now employing over 4,600 staff. Enseval became a publicly listed company on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing Kalbe Group products, Enseval is also entrusted by both domestic and international principals. The Company has an extensive distribution network with three Distribution Centers in Jakarta, Cikarang, and Surabaya, 48 branches across the Indonesian Archipelago, and 23 branches through its subsidiary PT Tri Sapta Jaya. To date, the Company has nine subsidiaries operating in distribution, raw materials, medical equipment, health services, and transportation services.